Home › Pain After Surgery › NCT07228039

ESP Blocks for Posterior Spinal Fusion

A Double-Blind Prospective RCT Assessment of ESP Blocks for Analgesia Following Posterior Spinal Fusion

Who can join

Ages 18 to 75 · All sexes

Inclusion Criteria

* English speaking
* Age 18-75
* ASA physical status 1-3
* Undergoing elective cervical or lumbar posterior spinal fusion (≤3 levels)

Exclusion Criteria

* Age \<18 or \>75
* ASA IV or V
* Non-English speaking
* BMI \>40
* Opioid dependence
* Chronic pain
* Anticoagulation or coagulopathy
* Injection site infection
* Hepatic or renal insufficiency
* Allergy to study drugs
* Pregnancy
* Inability to communicate with investigators

About the study

This prospective randomized double-blind study evaluates the efficacy of erector spinae plane (ESP) blocks on postoperative pain in patients undergoing cervical or lumbar posterior spinal fusion. Patients will receive either 0.5% bupivacaine plus liposomal bupivacaine or 0.5% plain bupivacaine. Outcomes include opioid consumption over 72 hours, pain scores, length of stay, and time to ambulation.

What is being tested

• ESP Block with Bupivacaine (drug)
• ESP Block with Bupivacaine + Liposomal Bupivacaine (drug)

Sponsor: Duke University · Participants: 75 · Started: Sep 17, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07228039

Locations in the U.S.

Conditions

• Pain After Surgery

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.